ClinicalTrials.gg
CompletedNCT03301779Updated Jun 23, 2020Results posted

Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial

A Phase 2 interventional study of Hemanext Red Blood Cell Processing System in Whole Blood Donation and Leukoreduction, sponsored by Hemanext. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-23.

Sponsored by Hemanext · Phase 2, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary goal of Hemanext. is to improve red cell storage through novel storage methods. Based on our review of the pertinent literature, there is substantial evidence suggesting that prolonged exposure to oxygen during storage results in oxidative damage to the red blood cells leading to decreased therapeutic potential. Therefore, removal of oxygen from red blood cell products prior to storage has potential to preserve the cells in a more physiologically relevant state.

Currently, Hemanext has focused on the design and development of a dual compartment bag system designated as the Hemanext Red Blood Cell Processing System. After standard processing of donated whole blood units into leukoreduced packed red blood cells (LR-RBCs) with the appropriate additive solutions, the LR-RBCs would then be placed in the oxygen reduction bag (ORB) which allows for the rapid diffusion of oxygen out of the blood, through a sterile, oxygen-permeable membrane, and into iron-based oxygen sorbents. After processing, the blood is transferred again from the ORB into the Hemanext storage bag (HSB) which will preserve the anaerobic state of the LR-RBC product for the duration of cold storage.

Hemanext has conducted preliminary storage tests to ascertain the effects of anaerobic storage on overall blood health in various storage solutions. The research team has focused primarily on percent hemolysis, which is mandated by the FDA to remain below 1% for the duration of storage, as well as ATP and 2,3-DPG levels.

Read the detailed description

In vitro and in vivo performance of O2/CO2 reduced red blood cells produced with the Hemanext System will be used to demonstrate the acceptability the final product for clearance. To accomplish this, the study will require a total of 100 studyevaluable donors. completing the study. The study entails a randomized, paired, 2-x-2 crossover design where every study donor (n = 10093) evaluable study donors who completes the study will donate a total of two whole blood units with individual units being donated at least 56 days (8 weeks) apart. One unit will be used as the test and the other unit will be used for the control. The order in which the IP and the CP will be used to collect, filter and store the whole blood and appropriate blood products (within the context of the crossover design) will be randomized.

02

Conditions studied

  • Whole Blood Donation and Leukoreduction

Keywords

  • Red Blood Cells
03

In context

Lead sponsor

Hemanext is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study donor must be ≥ 18 years of age.
  • Study donor must be ≥ 110 pounds.
  • Study donor's body temperature must be ≤ 37.5°C / 99.5°F (oral).
  • Study donor's must be ≥12.5 g/dL if female and ≥13.0 g/dL if male.
  • Study donor's hematocrit must be ≥ 38% if female and ≥39% if male.Study participants must meet EITHER hemoglobin or hematocrit criteria.
  • Study donor must meet all criteria per respective site's Research Blood Donation Record (BDR).
  • Study donor's most recent single RBC unit donation must have been ≥56 days prior to study donation.
  • Study donor's most recent double RBC unit donation must have been ≥ 112 days prior to study donation.
  • Study donor must have consented to study participation by reviewing and having expressed understanding the site-respective IRB-approved form prior to undergoing any study related procedures.

    21 CFR 50

  • Study donor's testing results from collected blood does not indicate a risk of transfusion-transmitted disease (TTD)*.
  • Study donors must agree to report adverse events from the time of signing the informed consent to twenty-four hours following the end of their active study involvement.
  • Female study donors must not be pregnant, expected to be pregnant or breastfeeding.
  • Female donors who participate in the in vivo portion of the study:

Women of child-bearing age must not be pregnant as determined by a negative pregnancy test prior to each re-infusion. If acceptable by local procedures, or surgically sterile women may be exempt from the pregnancy testing requirement.

Exclusion criteria

Exclusion Criteria:

  • Study donor is \< 18 years of age.
  • Study donor \< 110 pounds.
  • Study donor's body temperature is > 37.5°C / 99.5°F (oral).
  • Study donor's is \< 12.5 g/dL if female and \< 13.0 g/dL if male.
  • Study donor's hematocrit is \< 38% if female and \< 39% if male.
  • Study donor does not meet all criteria per respective site's Research Blood Donation Record (BDR).
  • Study donor's most recent single RBC unit donation was \< 56 days prior to study donation.
  • Study donor's most recent double RBC unit donation was \< 112 days prior to study donation.
  • Study donor has not consented to study participation.
  • Study donor's testing results from collected blood does indicate a risk of transfusion-transmitted disease (TTD)*.
  • Female donors who participate in the in vivo portion of the study: study donor is pregnant, expected to be pregnant or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Investigational Product

    Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System

    Device: Hemanext Red Blood Cell Processing System

  • No intervention
    Control Product

    Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.

Interventions

  • DeviceHemanext Red Blood Cell Processing System

    Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.

06

What researchers measure

Primary outcomes

  1. % of Red Blood Cells With Hemolysis

    Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.

    Time frame: On day 42 of storage

  2. Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells

    The mean 24-hour, post-transfusion, in vivo red blood cell recovery.

    Time frame: Day 42 of storage

  3. % Red Blood Cells Recovered Post-Filtration

    Percentage of red blood cells recovered after the filtration process.

    Time frame: Post-Filtration on Day 0

07

Results

Posted Mar 17, 2020
Limitations and caveats
Disclaimer: The 51-Cr/99-Tc(m) labeling for 14 study subjects occurred without prior RDRC approval and was done at a site that did not meet GMP standards.

Participant flow

Participant flow — Overall Study
MilestoneInvestigational Product First, Then Control ProductControl Product First, Then Investigational Product
Started4852
Completed4045
Not completed87

Outcome measures

Primary% of Red Blood Cells With Hemolysis

Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.

Time frame:
On day 42 of storage
Reported as:
Mean · % of Red Blood Cells with Hemolysis
% of Red Blood Cells With Hemolysis
% of Red Blood Cells with HemolysisInvestigational ProductControl Product
% of Red Blood Cells With Hemolysis0.29 ± 0.1680.29 ± 0.152
PrimaryDual Label 24 Hour In Vivo % Recovery of Red Blood Cells

The mean 24-hour, post-transfusion, in vivo red blood cell recovery.

Time frame:
Day 42 of storage
Reported as:
Mean · % Recovery of Red Blood Cells
Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells
% Recovery of Red Blood CellsInvestigational ProductControl Product
Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells89.3 ± 5.8185.8 ± 6.12
Primary% Red Blood Cells Recovered Post-Filtration

Percentage of red blood cells recovered after the filtration process.

Time frame:
Post-Filtration on Day 0
Reported as:
Mean · % of Red Blood Cells Recovered
% Red Blood Cells Recovered Post-Filtration
% of Red Blood Cells RecoveredInvestigational ProductControl Product
% Red Blood Cells Recovered Post-Filtration92.3 ± 1.991.1 ± 4.31

Adverse events

Collected over Study-related adverse events are defined as those study participant-reported adverse events occurring within 24-hours of donation and/or transfusion. Non-study-related adverse events outside of these periods were not recorded unless they were of a nature to impact study participant evaluability, safety or data validity.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Investigational Product0/100 (0%)1/100 (1%)9/100 (9%)
Control Product0/100 (0%)1/100 (1%)9/100 (9%)
Most frequent serious events
Most frequent serious events
EventInvestigational ProductControl Product
AppendicitsInfections and infestations1/1001/100
Most frequent other events
Most frequent other events
EventInvestigational ProductControl Product
Light-headedness after donationInjury, poisoning and procedural complications4/1004/100
Bruising or pain on arm at blood donation siteInjury, poisoning and procedural complications4/1004/100
Subject called to say he had dizziness at work after donation.Injury, poisoning and procedural complications1/1001/100
Dizzyness after donationInjury, poisoning and procedural complications1/1001/100
Nausea after donationInjury, poisoning and procedural complications1/1001/100
Cardiac AblationCardiac disorders1/1001/100
Side PainInfections and infestations1/1001/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Study Donors
Mean47.0 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)All Study Donors
Female47
Male53
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Donors
Hispanic or Latino2
Not Hispanic or Latino98
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Donors
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American10
White88
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Hoxworth Blood Center, University of Cincinnati
    Cincinnati, Ohio 45267-0055, United States
  • American Red Cross Mid-Atlantic Research Facility
    Norfolk, Virginia 23507, United States
  • Blood Center of Wisconsin
    Milwaukee, Wisconsin 53233, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2019, 15 months.

Results were first posted in Mar 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2017
First posted
Oct 4, 2017
StartActual
Nov 27, 2017
Primary completionActual
Mar 6, 2019
CompletionActual
Mar 6, 2019
Results first posted
Mar 17, 2020
Last update
Jun 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03301779
Lead sponsor
Hemanext
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Nov 27, 2017
Primary completion
Mar 6, 2019
Completion
Mar 6, 2019
Results posted
Mar 17, 2020
Last update
Jun 23, 2020

Study contacts

Faye West, MD
principal investigator · American Red Cross Mid-Atlantic Research Facility
Jose A Cancelas Perez, MD, PhD
principal investigator · Hoxworth Blood Center
Matthew Karafin, MD
principal investigator · Versiti

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion